GeoVax Advances Novel COVID-19 Vaccine and Cancer Therapies, Set to Present at Major Biotech Conference

GeoVax Labs, Inc. (Nasdaq: GOVX) is preparing to showcase its expanding portfolio of vaccine and immunotherapy developments at the upcoming 2025 BIO CEO & Investor Conference in New York, highlighting significant advancement in both infectious disease prevention and cancer treatment. The company's presentation comes at a crucial time as it moves forward with multiple Phase 2 clinical trials and a government-backed study that could reshape COVID-19 vaccination strategies.

At the center of GeoVax's developments is GEO-CM04S1, a next-generation COVID-19 vaccine that has garnered attention from the Biomedical Advanced Research and Development Authority (BARDA). The federal agency has commissioned GeoVax to conduct a 10,000-participant Phase 2b clinical trial comparing GEO-CM04S1's efficacy against currently approved COVID-19 vaccines, representing a significant vote of confidence in the company's technology.

The potential impact of GEO-CM04S1 extends beyond general population use. The vaccine is currently being evaluated in three separate Phase 2 clinical trials, addressing critical gaps in current COVID-19 protection strategies. One trial focuses on immunocompromised patients, particularly those with hematologic cancers who may not respond adequately to existing vaccines. Another trial examines its potential as a booster for chronic lymphocytic leukemia patients, while a third investigates its capability to provide more durable protection as a booster for individuals who previously received mRNA vaccines.

In the oncology sphere, GeoVax is advancing Gedeptin, a novel oncolytic solid tumor gene-directed therapy. Having completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers, the company is preparing to launch a Phase 2 trial in mid-2025 that will evaluate Gedeptin in combination with an immune checkpoint inhibitor for first recurrent head and neck cancer.

These developments are particularly significant for healthcare providers and patients seeking more effective solutions for both COVID-19 protection and cancer treatment. The company's focus on immunocompromised populations addresses a crucial medical need, as these patients often face increased vulnerability to infections and may not respond adequately to current vaccine options. Additionally, the advancement of Gedeptin represents potential progress in treating aggressive cancers that have limited treatment options.

The comprehensive approach to both infectious disease and cancer therapy, supported by the company's robust intellectual property portfolio, positions GeoVax at the intersection of two critical areas of medical research. The upcoming presentation at the BIO CEO & Investor Conference will provide deeper insights into the company's strategic vision and anticipated milestones for 2025, offering stakeholders a clearer picture of potential advances in vaccine and cancer treatment technologies.